◼ Archived
Business
🔮 fades ✓
Summit Packs A Punch For Merck's Keytruda
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Nsclc
5 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Nsclc
This hub groups 5 separate news trends connected to Nsclc, spanning July 2, 2026 through September 4, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 28 article observations and 26 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Health
Utah mom of five with Stage 4 lung cancer preparing for rare double-lung transplant
One Utah mother of five is preparing for a rare double-lung transplant after a stage 4 lung cancer diagnosis.
◼ Archived
Business
Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
Cullinan and Taiho's lung cancer drug has passed a major clinical trial, setting up a potential challenge to Johnson & Johnson's market-leading treatment.
◼ Archived
Health
🔮 fades ✓
Ask An Expert: What You Need to Know About Lung Cancer Testing
Lung cancer testing is evolving rapidly, with new advancements and barriers shaping patient care.
◼ Archived
Business
🔮 fades ✓
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche's KRAS G12C inhibitor, divarasib, outperformed rival therapies in a head-to-head Phase 3 trial for lung cancer.